ClinicalTrials.gg
RecruitingNCT07622602AromaQoRUpdated Nov 9, 2026

Impact of Topical Aromatherapy on Postoperative Quality of Recovery After Lung Resection

An interventional study of topical application of the "AromaQoR" formulation and topical application of sweet almond vegetable oil in Thoracic Surgical Procedures, Postoperative Recovery and Pain, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 9, 2026Now RecruitingFirst site in France+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Pain by University Hospital, Toulouse — 5 open to participants now, 5 under way, none of them phase 3. Pain · University Hospital, Toulouse.

Planned enrollment
3rd of 16
124 · median 29
Started
2026
with 4 others
No phase
9 of 22
4 open now
Registered
20th of 22
by date

Among the 22 studies in Pain by University Hospital, Toulouse, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 with no phase, and was the 20th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 22 studies in Pain by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Pain by University Hospital, Toulouse, or all of them as a file.
02

Study summary

The key to early surgery recovery lies in optimal and immediate control of postoperative pain. Despite standard pain management protocols, lung resection is often associated with acute, neuropathic, or chronic pain, compounded by the side effects of morphine-based treatments. In this context, aromatherapy can provide complementary support, both to alleviate pain and to improve the quality of recovery after surgery.

Read the detailed description

Lung cancer is the leading cause of cancer mortality in France. Lung resection is the standard treatment for early-stage or locally advanced non-small cell lung cancer, but it remains a very painful procedure with a high risk of complications and a morbidity rate of around 30%. Enhanced Recovery After Surgery (ERAS) protocols have reduced morbidity and mortality through standardized perioperative care. Early and optimal pain control is essential to promote rapid mobilization, limit complications, and prevent chronicity. Despite multimodal management, acute, neuropathic, and chronic pain remain common after lung resection and impair the quality of recovery.

Complementary approaches, such as aromatherapy, are increasingly used to support conventional treatments, sometimes reducing the use of morphine derivatives and their adverse effects. Lavender (Lavandula angustifolia) essential oil and its main components, linalool and linalyl acetate, whose antinociceptive, anti-inflammatory, and anxiolytic properties are well documented, is of particular interest. Our study will evaluate the effect of daily application of 5% lavender essential oil (AromaQoR) to the skin around the surgical wound for three days following surgery on improving the quality of recovery.

The surgeon preselects eligible patients and the coordinating nurse ("IDEC") presents the study to them during a preoperative interview. The day before surgery, the IDEC obtains consent, has the QoR-15F completed, and performs an AromaQoR skin test. On the morning of surgery, only patients without allergic reactions are included and then randomized into two groups: placebo (PL) or intervention (AT). From D0 to D2, the intervention (placebo or AromaQoR) is applied every evening, while the QoR-15F questionnaire is collected daily by a different team. Pain scores (EN, DN4) are measured regularly, with only those taken the following morning being recorded, and all rescue analgesics are recorded. A post-operative consultation is conducted three weeks after discharge, during which the IDEC measures the EN and DN4 and collects the QoR-15F questionnaire completed by the patient. This consultation marks the end of follow-up for the trial.

03

Conditions studied

  • Thoracic Surgical Procedures
  • Postoperative Recovery
  • Pain
  • Complementary Therapies
  • Aromatherapy

Browse trials for

Keywords

  • Quality of Recovery
  • Aromatherapy
  • Essential Oil
  • Thoracic surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older,
  • undergoing scheduled lung resection for diagnostic or therapeutic purposes
  • able to give free, informed, signed consent (no later than the day of inclusion and before any examination required by the research)
  • person affiliated with or beneficiary of a social security system.

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic pain prior to surgery
  • patients undergoing daily pain relief treatment prior to surgery
  • patients using essential oils applied to the skin for pain relief.
  • In relation to aromatherapy:
  • history of allergy to essential oils
  • atopic skin
  • known allergies
  • asthma
  • pregnant or breastfeeding women
  • nut allergies (in relation to sweet almond oil)
  • individuals who are vulnerable or deprived of their liberty by judicial or administrative decision
  • patients participating in other interventional studies on pain.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Placebo comparator
    PL =placebo

    The PL group: In addition to standard pain relief treatments, the PL group will receive topical application of sweet almond oil around the operated area at 9 p.m. from day 0 to day 2.

    Other: topical application of sweet almond vegetable oil

  • Experimental
    AT = aromatherapy

    The AT group: in addition to standard analgesic treatments, the AT group will receive topical application of the "AromaQoR" formulation, containing lavender essential oil (Lavandula angustifolia) diluted to 5% in sweet almond vegetable oil around the operated area at 9 p.m. from day 0 to day 2.

    Other: topical application of the "AromaQoR" formulation

Interventions

  • Othertopical application of the "AromaQoR" formulation

    topical application of the "AromaQoR" formulation, containing lavender essential oil (Lavandula angustifolia) diluted to 5% in sweet almond vegetable oil around the operated area

  • Othertopical application of sweet almond vegetable oil

    topical application of sweet almond oil around the operated area

06

What researchers measure

Primary outcomes

  1. Change in the total QoR-15F

    Change in the total QoR-15F score (Recovery Quality score) on postoperative day 2 (measured in the evening, as it assesses, among other things, activity during the day) compared to the baseline value obtained the day before surgery, day -1, between the two groups.

    Time frame: day 2

Secondary outcomes

  1. Change in the total QoR-15F score (Recovery Quality) on postoperative Day 1 (evening)

    Change in the total QoR-15F score (Recovery Quality) on postoperative D1 (evening) compared to the baseline value on Day-1

    Time frame: Day 1

  2. Change in the total QoR-15F score (Recovery Quality) on postoperative Day 3 (evening)

    Change in the total QoR-15F score (Recovery Quality) on postoperative Day 3 (evening) compared to the baseline value on Day-1

    Time frame: Day 3

  3. Change in the total QoR-15F score 3 weeks after discharge (postoperative consultation)

    Change in the total QoR-15F score 3 weeks after discharge (postoperative consultation) compared to the baseline value on D-1

    Time frame: Week 3

  4. Change in pain score at Day 0 (= day of surgery)

    pain score measured by numerical scale (EN) at each measurement time point compared to Day-1

    Time frame: Day 0

  5. Change in pain score at from postoperative Day 1 to postoperative Day 3 (morning, evening, night)

    pain score measured by numerical scale (EN) at each measurement time point compared to Day-1

    Time frame: Day 3

  6. Change in pain score at 3 weeks after discharge (day of postoperative consultation).

    pain score measured by numerical scale (EN) at each measurement time point compared to Day-1

    Time frame: week 3

  7. Quantification of the consumption of Nefopam

    number of ampoules consumed per day.

    Time frame: day 3

  8. Quantification of the consumption of morphine derivatives (prescribed as a second-line treatment if Nefopam is ineffective)

    number of tablets consumed per day

    Time frame: day 3

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 22 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 3, 2026
StartActual
Aug 12, 2026was Jun 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site added — first site in France
Show site
  • UHToulouse · Toulouse, France
Nov 9, 2026
Start date
Jun 2026→Aug 12, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • UHToulouse · Toulouse, France
    Start date Jun 2026→Aug 12, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07622602
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Aug 12, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

claudia Lavedan
Contact
lavedan.c@chu-toulouse.fr
5 67 77 18 74 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion